[1] Gu J,Jeong S,Xia Q.Intrahepatic cholangiocarcinoma arising from HBV Infection may be a highly selected population for liver transplantation.Hepatology,2017,66(5):1703-1704. [2] 乔莹,黄芬,蔡鑫泽,等.HBV感染诱发AID高表达与肝细胞癌变相关性研究.中华肿瘤防治杂志,2015,22(1):13-18. [3] 王晓玲,郝金翠,王春燕,等.趋化因子RANTES、IL-17以及TGF-β1在HBV-GN患者应用激素及免疫抑制剂的趋势研究.中国免疫学杂志,2018,34(10):1537-1541. [4] Sun L D,Qiao S,Wang Y,et al.Vγ 4+T cells:a novel IL-17-producing γδ T subsets during the early phase of chlamydial airway infection in mice.Mediat Inf Lamm,2018,2(18):1-10. [5] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版)[J].中华肝脏病杂志,2015,33(12):321-340. [6] 董博,胡海石,王德景,等.慢性乙型肝炎病毒感染患者血清HBV-LP水平与HBV-DNA及HBeAg的关系及临床意义.实用预防医学,2019,26(4):490-492. [7] 张志锋,孙业富,夏爱萍.外周血Th17及Th22对HBV相关肝硬化失代偿期的预测作用.肝脏,2018,23(6):561-562. [8] Chamoun MN,Blumenthal A,Sullivan MJ,et al.Bacterial pathogenesis and interleukin-17:interconnecting mechanisms of immune regulation,host genetics,and microbial virulence that influence severity of infection.Crit Rev Microbiol,2018,44(4):1-22. [9] 陈慧,顾兴华,吴敏娟,等.HBV感染不同病程中病毒载量与肝功能相关指标及免疫功能的变化分析.国际免疫学杂志,2015,38(2):138-142. [10] Wang T,Zhou X,Liu H,et al.Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis:A systematic review and meta-analysis.Phytother Res,2017,32(5):757-768. [11] 何胜,张震.血清IL-17水平及其基因多态性与HBV感染临床转归之间的关系研究.实用肝脏病杂志,2018,21(06):37-40. [12] 姚思敏,刘映霞,李晓鹤,等.慢性乙型肝炎患者外周血Th17细胞及相关转录因子表达的检测.中华实验和临床病毒学杂志,2015,29(1):2-6. [13] 黄玫,王岩,樊勇.新疆维吾尔族与汉族Graves病患者血清IL-17水平及其基因多态性研究.新疆医科大学学报,2015,38(4):437-440. [14] 孙志龙,单毓强,陈健忠,等.IL-17基因rs763780位点多态性与胃癌患者预后的关联性研究.中华全科医学,2015,13(10):1585-1587. [15] 钟慧筠,殷思纯.HBV相关慢加急性肝衰竭器官衰竭危险因素及短期预后分析.肝脏,2019,24(6):658-662. |